We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

185% more capital invested

Capital invested by funds: $359M → $1.02B (+$665M)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

158% more call options, than puts

Call options by funds: $21M | Put options by funds: $8.14M

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

32% more funds holding

Funds holding: 124 → 164 (+40)

20.94% more ownership

Funds ownership: 62.51% → 83.45% (+21%)

Holders
164
Holders Change
+40
Holders Change %
+32.26%
% of All Funds
2.02%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
68
Increased
55
Reduced
30
Closed
25
Calls
$21M
Puts
$8.14M
Net Calls
+$12.9M
Net Calls Change
+$13.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$46M
2
DTC
Deep Track Capital
Connecticut
+$39.8M
3
CC
Commodore Capital
New York
+$36M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32M
5
B
Braidwell
Connecticut
+$28M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
2
Morgan Stanley
Morgan Stanley
New York
-$17.1M
3
MB
MPM BioImpact
Massachusetts
-$17.1M
4
ACM
ADAR1 Capital Management
Texas
-$6.03M
5
Jane Street
Jane Street
New York
-$5.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAP
76
Persistent Asset Partners
Hong Kong
$908K +$990K +62,051 New
SEI Investments
77
SEI Investments
Pennsylvania
$890K +$971K +60,848 New
AA
78
Ancora Advisors
Ohio
$801K +$113K +7,101 +15%
Deutsche Bank
79
Deutsche Bank
Germany
$797K -$24.9K -1,560 -3%
PA
80
Profund Advisors
Maryland
$735K +$210K +13,172 +36%
SGM
81
Seven Grand Managers
New York
$732K +$798K +50,000 New
HP
82
Hikari Power
Japan
$731K – – –
VGA
83
Vanguard Global Advisers
Pennsylvania
$698K +$761K +47,688 New
Jane Street
84
Jane Street
New York
$651K -$5.33M -333,824 -88%
Creative Planning
85
Creative Planning
Kansas
$630K +$61.5K +3,854 +10%
Massachusetts Financial Services
86
Massachusetts Financial Services
Massachusetts
$606K +$661K +41,416 New
Franklin Resources
87
Franklin Resources
California
$572K +$624K +39,081 New
Susquehanna International Group
88
Susquehanna International Group
Pennsylvania
$565K -$369K -23,118 -37%
Invesco
89
Invesco
Georgia
$559K -$85.7K -5,371 -12%
Mirae Asset Global ETFs Holdings
90
Mirae Asset Global ETFs Holdings
Hong Kong
$548K +$91.7K +5,743 +18%
SG Americas Securities
91
SG Americas Securities
New York
$518K +$246K +15,399 +77%
Simplex Trading
92
Simplex Trading
Illinois
$508K +$554K +34,723 New
XT
93
XTX Topco
Cayman Islands
$502K +$547K +34,305 New
Qube Research & Technologies (QRT)
94
Qube Research & Technologies (QRT)
United Kingdom
$486K -$1.3M -81,272 -71%
AIM
95
Avity Investment Management
Connecticut
$486K +$8.3K +520 +2%
MIM
96
MetLife Investment Management
New Jersey
$484K +$37K +2,318 +8%
VIA
97
Virtus Investment Advisers
Connecticut
$477K +$12.7K +796 +3%
AllianceBernstein
98
AllianceBernstein
Tennessee
$475K +$712K +44,620 +261%
MMA
99
Miracle Mile Advisors
California
$439K +$479K +30,000 New
OF
100
Optimize Financial
California
$411K +$448K +28,060 New
2 3
4
5 6

CRVS Hedge Fund Activity: Q1 2026 in Review

164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.

  • 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
  • Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
  • 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q1 2026.